Evidence-Based Complementary and Alternative Medicine

Research Article

Potent Antifungal Activity of Pure Compounds from Traditional Chinese Medicine Extracts against Six Oral Candida Species and the Synergy with Fluconazole against Azole-Resistant Candida albicans

Table 3

In vitro interaction of pseudolaric acid B and fluconazole (1 : 1) against oral Candida spp.


Strain	Agent	MIC(μg/mL)		FIC	FICI	Outcome
Strain	Agent	Alone	Combination	FIC	FICI	Outcome

C. albicans (M3)	FLZ	64	1	1/64	<0.5	Synergy
	PSE	32 (0.074)*	1	1/32
C. krusei (K2)	FLZ	16	16	1	0.5–4	No interaction
	PSE	64 (0.148)	16	16/64
C. tropicalis (T1)	FLZ	0.25	0.25	1	0.5–4	No interaction
	PSE	16 (0.037)	0.25	0.25/16
C. dubliniensis (D4)	FLZ	32	32	1	0.5–4	No interaction
	PSE	64 (0.148)	32	32/64
C. glabrata (gp)	FLZ	0.5	0.5	1	0.5–4	No interaction
	PSE	32 (0.074)	0.5	0.5/32
C. guilliermondii (gm3)	FLZ	2	2	1	0.5–4	No interaction
	PSE	32 (0.074)	2	2/32

MIC: Minimum inhibitory concentration; FIC: fractional inhibitory concentration; FICI: fractional inhibitory concentration index; PSE: pseudolaric acid B; FLZ: fluconazole; M, K2, T1, D4, gp, gm3: strain no. *Concentration in micromolar.